Bea Jennifer W, Jurutka Peter W, Hibler Elizabeth A, Lance Peter, Martínez Maria E, Roe Denise J, Sardo Molmenti Christine L, Thompson Patricia A, Jacobs Elizabeth T
University of Arizona Cancer Center, 1515N. Campbell Avenue, Tucson, AZ 85724-5024, USA.
School of Mathematical and Natural Sciences, Arizona State University, 4701W. Thunderbird Rd, Phoenix, AZ 85306, USA.
Metabolism. 2015 Mar;64(3):447-59. doi: 10.1016/j.metabol.2014.11.010. Epub 2014 Nov 29.
Few epidemiological studies have investigated the association between circulating concentrations of the active vitamin D metabolite 1,25(OH)2D and metabolic syndrome. We sought to determine whether blood levels of 1,25(OH)2D are associated with metabolic syndrome and its individual components, including waist circumference, triglycerides, blood pressure, and glucose, and high-density lipoprotein. We also investigated these associations for the more abundant precursor vitamin D metabolite, 25(OH)D.
Participants from two completed clinical trials of colorectal neoplasia with available metabolic syndrome data and blood samples for measurement of 1,25(OH)2D (n=1048) and 25(OH)D (n=2096) were included. Cross-sectional analyses of the association between concentrations of 1,25(OH)2D, 25(OH)D, metabolic syndrome, and its components were conducted.
A statistically significant inverse association was observed for circulating concentrations of 1,25(OH)2D and metabolic syndrome, with adjusted ORs (95% CIs) of 0.73 (0.52-1.04) and 0.52 (0.36-0.75) for the second and third tertiles of 1,25(OH)2D, respectively (p-trend <0.001). Significant inverse relationships were also observed between 1,25(OH)2D and high triglycerides (p-trend <0.001), and low high-density lipoprotein (p-trend <0.001). For 25(OH)D concentrations, significant inverse associations were found for metabolic syndrome (p-trend <0.01), high waist circumference (p-trend <0.04) and triglyceride levels (p-trend <0.01). Participants with 25(OH)D ≥30 ng/ml and in the highest tertile of 1,25(OH)2D demonstrated significantly lower odds of metabolic syndrome, with an OR (95% CI) of 0.38 (0.19-0.75) compared to those in the lowest category for both metabolites.
These results provide new evidence that the relatively rarely-studied active hormonal form of vitamin D, 1,25(OH)2D, is associated with metabolic syndrome and its components, and confirm prior findings for 25(OH)D. The finding that 1,25(OH)2D is related to high-density lipoprotein, while 25(OH)D is not, suggests that there may be an independent mechanism of action for 1,25(OH)2D in relation to metabolic dysregulation.
很少有流行病学研究调查活性维生素D代谢物1,25(OH)₂D的循环浓度与代谢综合征之间的关联。我们试图确定1,25(OH)₂D的血液水平是否与代谢综合征及其各个组分相关，这些组分包括腰围、甘油三酯、血压、血糖以及高密度脂蛋白。我们还研究了更为丰富的维生素D前体代谢物25(OH)D的这些关联。
纳入来自两项已完成的结直肠肿瘤临床试验的参与者，这些参与者有可用的代谢综合征数据以及用于测量1,25(OH)₂D的血样（n = 1048）和25(OH)D的血样（n = 2096）。对1,25(OH)₂D、25(OH)D的浓度与代谢综合征及其组分之间的关联进行横断面分析。
观察到1,25(OH)₂D的循环浓度与代谢综合征之间存在统计学显著的负相关，1,25(OH)₂D第二和第三三分位数的校正比值比（95%置信区间）分别为0.73（0.52 - 1.04）和0.52（0.36 - 0.75）（p趋势<0.001）。在1,25(OH)₂D与高甘油三酯（p趋势<0.001）以及低高密度脂蛋白（p趋势<0.001）之间也观察到显著的负相关关系。对于25(OH)D浓度，在代谢综合征（p趋势<0.01）、高腰围（p趋势<0.04）和甘油三酯水平（p趋势<0.01）方面发现了显著的负相关。25(OH)D≥30 ng/ml且处于1,25(OH)₂D最高三分位数的参与者代谢综合征的几率显著更低，与两种代谢物最低类别参与者相比，比值比（95%置信区间）为0.38（0.19 - 0.75）。
这些结果提供了新的证据，表明相对较少研究的活性激素形式的维生素D，即1,25(OH)₂D，与代谢综合征及其组分相关，并证实了先前关于25(OH)D的研究结果。1,25(OH)₂D与高密度脂蛋白相关而25(OH)D不相关这一发现表明，1,25(OH)₂D在代谢失调方面可能存在独立的作用机制。
